Navigation Links
Fate Therapeutics' iPSC Technology Awarded Top Industry Honors for Small Molecule and Protein Reprogramming Breakthroughs
Date:12/21/2009

SAN DIEGO, Dec. 21 /PRNewswire/ -- Fate Therapeutics, Inc. announced today that the Company's iPSC technology platform, developed with Sheng Ding, Ph.D., has been honored as the Top Innovation of 2009 by The Scientist and has received the 2009 North American Technology Innovation Award from Frost & Sullivan. These notable awards recognize Fate Therapeutics for advancing minimally invasive techniques for the reprogramming and differentiation of induced pluripotent stem cells (iPSCs), including the protein-induced reprogramming technologies pioneered by Dr. Ding, associate professor at The Scripps Research Institute and a scientific founder of Fate Therapeutics. Earlier this year, under a research collaboration with Fate Therapeutics and The Scripps Research Institute, Dr. Ding and his team of scientists became the first group to accomplish the extraordinary feat of iPSC generation without genetic manipulation.

"We are honored to receive these recognitions of achievement and thankful for the contributions of our Scientific Founders," said Paul Grayson, president and CEO of Fate Therapeutics. "By building on their pioneering research, we are striving to create an industry admired stem cell biology drug discovery engine for the identification and development of small molecules and biologics to modulate cell fate for therapeutic benefit."

Fate Therapeutics utilizes the most advanced reprogramming and differentiation technologies for generating cell types of interest to elucidate disease biology and identify targets for therapeutic intervention. The Company's protein-based reprogramming platform in combination with its novel small molecule conditions offers a highly efficient, non-viral, non-DNA based m
'/>"/>

SOURCE Fate Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. European Medicines Agency Grants Cell Therapeutics Orphan Drug Designation for Pixantrone in Diffuse Large B-Cell Lymphoma (DLBCL)
2. Cornerstone Therapeutics to Host Conference Call to Discuss Financial Guidance for 2010
3. Cell Therapeutics Announces FDAs Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma, February 10, 2010
4. Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company
5. Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
6. Oxygen Biotherapeutics, Inc. Expands Board of Directors
7. Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign
8. Drug Candidates in Pipeline Offer Potential for Parkinsons Disease Therapeutics Market, Says Frost & Sullivan
9. Hemodynamic Therapeutics Announces Successful Completion of Initial Phase 2 Clinical Study for Novel Combination Hypertension Therapy
10. Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing
11. Oxygen Biotherapeutics, Inc. Enrolls First Patient in Traumatic Brain Injury Clinical Trial in Switzerland
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... MENLO PARK, Calif. , June 1, 2015 /PRNewswire/ ... medical device company that is providing innovative evidence-based solutions ... it has commenced an underwritten public offering of its ... by Nevro and 2,459,175 shares to be sold by ... grant the underwriters a 30-day option to purchase up ...
(Date:6/1/2015)... MENLO PARK, Calif. , June 1, ... (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical ... therapies in new orphan drug indications, today announced ... trial of  VAL-083  (dianhydrogalactitol) in patients with refractory ... form of human brain cancer. Results ...
(Date:6/1/2015)... CEFALY Technology , the creators of ... authorized for use prior to the onset of migraine ... trial showing that the Cefaly device returns normal metabolic ... patients, namely the orbitofrontal cortex and rostral cingulate. ... an imaging test of the brain, used a radioactive substance called a ...
Breaking Medicine Technology:Nevro Announces Proposed Public Offering of Common Stock 2Nevro Announces Proposed Public Offering of Common Stock 3DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 2DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 3DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 4DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 5DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 6DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 7DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 8New Study Shows CEFALY Returns Normal Metabolic Activity to Brain Areas in Migraine Patients 2
... Clinical Development for the Treatment of ... Opioid Bowel Dysfunction, ... presented positive results this week from Phase,1 and preclinical studies of ... in Las Vegas, Nevada. NKTR-118 is,Nektar,s proprietary oral therapy being studied ...
... physician leading clinical trials, FREEPORT, N.Y., ... in treating facial bruising from injectable cosmetic,treatments ... known for,treating under-eye circles. Pinoxide is ... (BMTd),created by AGI Dermatics and formulated in ...
Cached Medicine Technology:Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting 2Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting 3Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting 4Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting 5Promising Results in Treating Facial Bruising From Injectables 2
(Date:6/1/2015)... 2015 On May 14, 2015, the ... hosted the Cherry Creek Chamber of Commerce for the ... care centers typically do not offer primary care services ... Cherry Creek Urgent Care staff to schedule family care ... 5:30 to 7:30 p.m. the center hosted presidents, CEOs, ...
(Date:6/1/2015)... Portland, Ore. (PRWEB) June 01, 2015 ... Plans (AHIP) announced today a new, interactive Affordable ... support large employers. The course, called “Affordable Care ... care professionals with the strategic and consultative insights ... employers as they navigate the impacts of the ...
(Date:6/1/2015)... June 01, 2015 Note: Dr. Julian ... in breast cancer prevention. , A phase III trial ... postmenopausal women with ductal carcinoma in situ (DCIS) now ... prevention. , The study (NSABP B-35/NRG Oncology) looked at ... the standard five-year treatment with tamoxifen to those who ...
(Date:6/1/2015)... June 01, 2015 More than 22 million ... months when school is out and they lose access to ... and America’s dairy farmers and milk companies are on a ... with The Great American Milk Drive. , In many ... in the school cafeteria for the bulk of their daily ...
(Date:6/1/2015)... 2015 June 1, 2015 – Atlanta, ... in the areas of hospital medicine, emergency medicine, and ... has expanded upon its partnership with AgileMD to provide ... Practice, in a mobile application format available on ... “We are very excited about the June 1 launch ...
Breaking Medicine News(10 mins):Health News:Grand Opening For AFC/Doctors Express Cherry Creek Primary Care Clinic 2Health News:Cambia Partners with AHIP to Offer Expert Series ACA Training Course 2Health News:Cambia Partners with AHIP to Offer Expert Series ACA Training Course 3Health News:Today at ASCO: Anastrazole Offers Higher Breast Cancer-Free Survival Rates than Tamoxifen Following DCIS, Phase III Study Shows 2Health News:Today at ASCO: Anastrazole Offers Higher Breast Cancer-Free Survival Rates than Tamoxifen Following DCIS, Phase III Study Shows 3Health News:Summer Nutrition Vital for Kids who Depend on Schools for Healthy Foods 2Health News:EB Medicine Expands Partnership With AgileMD To Launch Hospital Medicine Mobile Application 2Health News:EB Medicine Expands Partnership With AgileMD To Launch Hospital Medicine Mobile Application 3
... , ... Data Advantage, LLC recently named two QHR ... list. Fort Madison Community Hospital (Fort Madison, Iowa), a QHR management ... management client since 1979, were lauded by the company, which specializes ...
... Dec. 20 (HealthDay News) -- Think twice before you put that ... You may get it and find out you don,t really need ... a new study suggests. , That,s because "sometimes the reality of ... cappuccino machine is a hassle to clean, the fancy navigation system ...
... ... Province of Quebec following an inquiry that suggested that there might have been testing ... ... served as the reference laboratory for a highly anticipated retesting of nearly 3,000 breast ...
... , WASHINGTON, Dec. 20 ... Bureau: , (Logo: http://www.newscom.com/cgi-bin/prnh/20090226/CENSUSLOGO ) , SUNDAY, DECEMBER ... Sunday, December 20th. The first successful organ transplant in the U.S. ... Joseph Murray. He transplanted a kidney from one identical twin ...
... , , Federal government must not ... not go forward unless and until problems remedied , ... affordability top issues , WASHINGTON, Dec. 19 The ... current form, Cardinal Daniel DiNardo of Galveston-Houston, Bishop William Murphy ...
... electronic health records, concerns about potential privacy breaches remain an ... 2010 issue of the Journal of the American Informatics ... one of 30 specialty titles published by the BMJ ... published study is based on views of more than 1,000 ...
Cached Medicine News:Health News:QHR Hospital Clients Fort Madison Community Hospital, Monroe County Hospital Named to “Best in Value” Top 100 List 2Health News:Be Careful What You Wish For This Holiday Season 2Health News:Seattle-based PhenoPath Laboratories Retests Nearly 3,000 Breast Cancer Specimens from Quebec Breast Cancer Inquiry 2Health News:Seattle-based PhenoPath Laboratories Retests Nearly 3,000 Breast Cancer Specimens from Quebec Breast Cancer Inquiry 3Health News:U.S. Census Bureau Daily Feature for Dec. 20 2Health News:Health Reform Bill Needs More Work Despite New Language on Abortion, Say Catholic Bishops 2Health News:Health Reform Bill Needs More Work Despite New Language on Abortion, Say Catholic Bishops 3Health News:Health Reform Bill Needs More Work Despite New Language on Abortion, Say Catholic Bishops 4Health News:Journal of the American Medical Informatics Association 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: